Is NCT07528352 recruiting in Salt Lake City, UT?

Yes, NCT07528352 is currently recruiting participants at its Salt Lake City, UT location. This diffuse large b cell lymphoma clinical trial is actively enrolling qualified participants.

How do I join the diffuse large b cell lymphoma clinical trial in Salt Lake City?

To join this clinical trial in Salt Lake City, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Salt Lake City clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Diffuse Large B Cell Lymphoma Clinical Trial in Salt Lake City, UT

Who Can Participate

Inclusion Criteria

Participant aged ≥ 18 years

Disease criteria:

Histologically confirmed large b-cell lymphoma (LBCL), including DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma with:

Relapsed or refractory disease with at least 2 prior systemic therapies

Must be a candidate for radiation therapy up to 20 Gy. Radiation therapy to up to 3 lesions will be permitted.

Must have at minimum two sites of evaluable disease per Lugano 2014, including one site that will not be irradiated as part of this study and has not received radiation therapy in the past.

ECOG Performance Status ≤ 3

Adequate organ function as defined as --Hematologic:

Absolute neutrophil count ≥ 1000/mm3 (Note: Use of G-CSF is permitted)

Platelet count ≥ 50,000/mm3 (Note: Use of platelet transfusions is permitted)

Hemoglobin ≥ 7 g/dL, (Note: Blood transfusions are permitted) --Hepatic:

Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)

AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN. --Renal:

Estimated creatinine clearance ≥ 40 mL/min by Cockcroft-Gault formula.

Participants must adhere to the following sex and contraceptive/barrier requirements:

If participant is of childbearing potential they must have a negative pregnancy test

For participants of non-child bearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

\< 50 years of age: ---Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and

Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution --≥ 50 years of age:

Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or

Had radiation-induced menopause with last menses \>1 year ago; or

Had chemotherapy-induced menopause with last menses \>1 year ago

Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution

Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Sections 5.4.1 and 5.4.2.

Clinically significant adverse effects from any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy) must have resolved or have been determined to be clinically stable per the Investigator.

Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

Currently receiving any other approved or investigational therapy considered as a treatment for lymphoma with the exception of corticosteroids.

Progressive disease on prior CD20 x CD3 bispecific antibody --Note: Prior therapy with CD20 x CD3 bispecific antibody is allowed.

Prior systemic anti-cancer therapy which may have delayed treatment effects (e.g. immunotherapy) ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.

The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study.

Known brain metastases or cranial epidural disease. --Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Participants must be neurologically stable and receiving a stable or decreasing corticosteroid dose at the time of study entry

Significant medical diseases or other conditions, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study.

Active systemic bacterial, viral, fungal or other infection requiring systemic treatment at time of screening.

Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. --Note: Participants on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.

Hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C. --Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.

Unable to tolerate corticosteroids

Participants taking prohibited medications as described in Section 6.6.1.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT07528352) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diffuse Large B Cell Lymphoma Treatment Options in Salt Lake City, UT

If you're searching for diffuse large b cell lymphoma treatment options in Salt Lake City, UT, this clinical trial (NCT07528352) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced diffuse large b cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diffuse large b cell lymphoma clinical trials near you to find additional studies recruiting in your area.

Diffuse Large B Cell Lymphoma Clinical Trial in Salt Lake City, UT

Expert Care in Salt Lake City

IRB Approved

No-Cost Care

Apply for This Salt Lake City Location

Why Participate?

Simple Process

About This Diffuse Large B Cell Lymphoma Study in Salt Lake City